Current estimates indicate 650 million people are obese globally, and the US alone spends $173 Bn/year in obesity-related healthcare costs. Airfinity forecasts that treating just half of all severely obese patients with metabolic syndrome would generate an $80 Bn market by 2030 in the US, growing more than 30X from today’s $2.2 Bn.
In response to this fast moving landscape, Airfinity has launched a weekly obesity market intelligence newsletter, providing independent analysis, as well as a curated summary of the latest news, commentary, and scientific results delivered to your inbox every week.
Our team of specialised analysts and scientists monitor and assess the entire anti-obesity landscape, spanning hundreds of data sources and channels, in order to get you the most important information and give answers to the critical questions.
Learn more about what is included in the newsletter and how to subscribe here.
To discuss access to Airfinity's independent forecasts and disease modelling, including the impact of anti-obesity drug uptake on cardiovascular outcomes, get in touch here.